| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/26/2013 | CN103173460A Allogeneic tumor therapeutic agent |
| 06/26/2013 | CN103173459A Mouse-anti-human T cell antigen ZCH-2B8a monoclonal antibody variable region gene and use |
| 06/26/2013 | CN103173419A Chemokine-4 resisting monoclonal antibody, chemokine-4 resisting hybridoma cell line and applications of monoclonal antibody |
| 06/26/2013 | CN103172751A Fusion protein of PA4-Fc and coding gene and application thereof |
| 06/26/2013 | CN103172749A Preparation of African swine fever protein engineering vaccine |
| 06/26/2013 | CN103172746A Tripolymer fc fusion proteins and use thereof |
| 06/26/2013 | CN103172744A Monoclonal antibodies for specifically identifying B-Raf mutant proteins, preparation method and applications thereof |
| 06/26/2013 | CN103172743A Human Antibodies That Bind Cd22 And Uses Thereof |
| 06/26/2013 | CN103172742A Antibodies specific for human CD22 and their therapeutic and diagnostic uses |
| 06/26/2013 | CN103172741A New fully human antibody |
| 06/26/2013 | CN103172739A IL-12/P40 binding proteins |
| 06/26/2013 | CN103172738A IL-12/P40 binding proteins |
| 06/26/2013 | CN103172737A IL-12/P40 binding proteins |
| 06/26/2013 | CN103172736A Humanized monoclonal antibodies to hepatocyte growth factor |
| 06/26/2013 | CN103172735A Anti-system asc amino acid transporter 2 (asct2) antibody |
| 06/26/2013 | CN103172734A Humanized anti-anthrax-toxin protective antigen neutralizing antibody Fab and applications thereof |
| 06/26/2013 | CN103172710A Modified influenza virus for monitoring and improving vaccine efficiency |
| 06/26/2013 | CN103172709A IBDV (Infectious Bursal Disease Virus) VP2 protein and IBD subunit vaccine |
| 06/26/2013 | CN103172705A Hepatitis C virus (HCV) B cell epitope peptide PUHI16 and application thereof |
| 06/26/2013 | CN103172703A Tuberculosis-resisting-drug-related efflux-protein-sourced tuberculosis resisting CTL (Cytotoxic T Lymphocyte) epitope peptide and application thereof |
| 06/26/2013 | CN103172702A Tuberculosis-resisting-drug-related efflux-protein-sourced tuberculosis resisting CTL (Cytotoxic T Lymphocyte) epitope peptide and application thereof |
| 06/26/2013 | CN103169986A Mosaic type DNA (Deoxyribonucleic Acid) vaccine pVAXI-Hsp 70/CD 80 for preventing and immunologically treating tuberculosis |
| 06/26/2013 | CN103169978A Temperature control slow release injection for bird immune globulin as well as preparation method and application thereof |
| 06/26/2013 | CN103169970A Pharmaceutical composition for treating viral pneumonia |
| 06/26/2013 | CN103169967A Composition for improving female rate of chick embryos and preparation of composition |
| 06/26/2013 | CN103169966A Medicinal composition for treating systemic lupus erythematosus |
| 06/26/2013 | CN103169965A Treatment for multiple sclerosis |
| 06/26/2013 | CN103169964A Freeze-drying protective additive of feline panleukopenia attenuated freeze-dried vaccine |
| 06/26/2013 | CN103169963A Building and application of hydrophobia DNA (deoxyribonucleic acid) vaccine |
| 06/26/2013 | CN103169962A Anti-foot-and-mouth disease vaccine composition and preparation and application thereof |
| 06/26/2013 | CN103169961A Method for producing type 2 capsid protein grain vaccine of porcine circovirus by pichia pastoris expression system |
| 06/26/2013 | CN103169960A 免疫原性组合物 The immunogenic composition |
| 06/26/2013 | CN103169959A Compositions and methods for treating tumors presenting survivin antigens |
| 06/26/2013 | CN103169958A Survivin peptide vaccine |
| 06/26/2013 | CN103169773A Traditional Chinese medicine compound preparation for enhancing livestock immunity and preparation method |
| 06/26/2013 | CN102350889B Batch preparation method for pattern coded microcarrier |
| 06/26/2013 | CN102277384B PSA recombinant adeno-associated viral vector and its construction method and application |
| 06/26/2013 | CN102178943B Cross protection vaccine |
| 06/26/2013 | CN102085363B Vibrio cholerae O139 capsular polysaccharide conjugate vaccine and preparation method thereof |
| 06/26/2013 | CN101611058B Prlr-specific antibody and uses thereof |
| 06/26/2013 | CN101605560B A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma |
| 06/26/2013 | CN101454023B Defective interfering virus |
| 06/26/2013 | CN101426906B A novel class of therapeutic protein based molecules |
| 06/26/2013 | CN101365479B Chimeric viruses presenting non-native surface proteins and uses thereof |
| 06/25/2013 | US8470980 Extracellular targeted drug conjugates |
| 06/25/2013 | US8470979 Humanized antibody molecules specific for IL-31 |
| 06/25/2013 | US8470978 Method for separating viable cells, apoptotic and dead cells |
| 06/25/2013 | US8470974 Method for highly sensitive detection of protein-protein interaction |
| 06/25/2013 | US8470798 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 06/25/2013 | US8470793 Down-regulation of mortalin by siRNA |
| 06/25/2013 | US8470774 Deoxycorticosterone induced elastin production |
| 06/25/2013 | US8470768 Peptide epitopes of apolipoprotein B |
| 06/25/2013 | US8470598 Modified Vaccinia Ankara virus variant and cultivation method |
| 06/25/2013 | US8470585 Process for adenovirus purification from high cell density cultures |
| 06/25/2013 | US8470578 Purification of vaccinia viruses using hydrophobic interaction chromatography |
| 06/25/2013 | US8470577 Viral vectors and their use in therapeutic methods |
| 06/25/2013 | US8470560 CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines |
| 06/25/2013 | US8470527 Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties |
| 06/25/2013 | US8470372 Material with immunogenicity |
| 06/25/2013 | US8470343 Immunogenic compositions and uses thereof |
| 06/25/2013 | US8470342 Methods of altering an immune response induced by CpG oligodeoxynucleotides |
| 06/25/2013 | US8470341 Escherichia coli immunogens with improved solubility |
| 06/25/2013 | US8470340 Peptides presenting an epitope of a domain of factor H binding protein and methods of use |
| 06/25/2013 | US8470339 Antigens for paratuberculosis diagnosis and vaccination |
| 06/25/2013 | US8470338 Method for preventing or treating M tuberculosis infection |
| 06/25/2013 | US8470337 Therapeutic treatments using botulinum neurotoxin |
| 06/25/2013 | US8470336 immunization against proliferative enteritis, known as ileitis |
| 06/25/2013 | US8470335 Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it |
| 06/25/2013 | US8470334 Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics |
| 06/25/2013 | US8470333 Chimeric peptides comprising HER-2 B-cell epitopes and T-helper epitopes |
| 06/25/2013 | US8470331 Induce immunology response; antiallergens; bioavailability; autoimmune disease, anticancer agents, antiallergens |
| 06/25/2013 | US8470330 PSMA antibodies and uses thereof |
| 06/25/2013 | US8470329 Combination therapy with antibody-drug conjugates |
| 06/25/2013 | US8470328 Purification method which prevents denaturation of an antibody |
| 06/25/2013 | US8470327 Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
| 06/25/2013 | US8470326 Monoclonal antibody therapy for pancreas cancer |
| 06/25/2013 | US8470325 Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
| 06/25/2013 | US8470324 Fusion polypeptides capable of activating receptors |
| 06/25/2013 | US8470323 Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display |
| 06/25/2013 | US8470322 Anti sulfatides and anti sufated proteoglycans antibodies and their use |
| 06/25/2013 | US8470321 Antibodies specific for the protofibril form of beta-amyloid protein |
| 06/25/2013 | US8470320 Humanised antibodies with anti-tumour activity |
| 06/25/2013 | US8470318 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| 06/25/2013 | US8470317 B7RP-1 antagonists |
| 06/25/2013 | US8470316 Agents for suppressing damage to transplanted islets after islet transplantation |
| 06/25/2013 | US8470315 Non-natural ribonuclease conjugates as cytotoxic agents |
| 06/25/2013 | US8470314 Modified toxins |
| 06/25/2013 | US8470313 Ras mutation and compositions and methods related thereto |
| 06/25/2013 | CA2653566C Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 06/25/2013 | CA2627598C Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 06/25/2013 | CA2573586C Il-17 antagonistic antibodies |
| 06/25/2013 | CA2573505C N-glycosylated antibody |
| 06/25/2013 | CA2545255C Interleukin-10 antibodies |
| 06/25/2013 | CA2522894C Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| 06/25/2013 | CA2496422C Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 06/25/2013 | CA2495725C Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody |
| 06/25/2013 | CA2492097C Signal for packaging of influenza virus vectors |
| 06/25/2013 | CA2454920C Antigenic compositions |
| 06/25/2013 | CA2454578C Modified human thymic stromal lymphopoietin |
| 06/25/2013 | CA2428744C Inhibition of lysozyme in treating sepsis-induced myocardial dysfunction |